Trials / Completed
CompletedNCT02145143
Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study
- Status
- Completed
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to find out what effects, good and/or bad, a drug called vemurafenib, either alone or combined with another treatment called radioactive iodine, has on the patient and thyroid cancer. It is not known if vemurafenib works against thyroid cancer. This study will test in a small number of patients if it can be used with radioactive iodine to treat thyroid cancers. This type of study is called a pilot study. If the results are positive, a larger study with more patients may be done to further test this treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vemurafenib | |
| DEVICE | serial 124I PET/CT | |
| DRUG | thyrotropin alpha |
Timeline
- Start date
- 2014-05-20
- Primary completion
- 2024-11-21
- Completion
- 2024-11-21
- First posted
- 2014-05-22
- Last updated
- 2025-06-18
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02145143. Inclusion in this directory is not an endorsement.